Ovarian CanceRx | Leadership

Ovarian CanceRx Leadership

Beth Y. Karlan, MD

Director, Cancer Population Genetics
UCLA, Jonsson Comprehensive Cancer Center

Chair, Steering Committee

Joyce F. Liu, MD, MPH

Associate Chief and Director of Clinical Research, Division of Gynecologic Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine,
Harvard Medical School

Co-Chair, Clinical Leadership

Andrew W. Lo, PhD

Charles E. and Susan T. Harris Professor, Finance
Director, Laboratory for Financial Engineering
MIT Sloan School of Management

Chair, Financial Innovation and Strategy

Ursula A. Matulonis, MD

Chief, Division of Gynecologic Oncology
Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School

Chair, Arm Selection Committee

Kunle Odunsi, MD, PhD

Director, Comprehensive Cancer Center
Biological Sciences Division Dean for Oncology
University of Chicago Medicine

Co-Chair, Translational Leadership

Lynda D. Roman, MD

Associate Professor of Obstetrics and Gynecology
Division Chief, Gynecologic Oncology
Keck School of Medicine of USC

Chair, Clinical Leadership

Anil K. Sood, MD

Professor and Vice-Chair for Translational Research in the Departments of Gynecologic Oncology and Cancer Biology
The University of Texas MD Anderson Cancer Center

Chair, Translational Leadership

Shannon N. Westin, MD, MPH, FACOG

Professor and Clinical Medical Director, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery,
The University of Texas MD Anderson Cancer Center

Co-Director, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Co-Chair, Arm Selection Committee

5

Ovarian cancer accounts for 5% of all cancer death in women

90

Cases detected early have a +90% survival rate after 5 years

45

Women with BRCA1 gene mutation have a 45% lifetime risk of ovarian cancer

Ovarian CanceRx

Rapid. Adaptive. Needed.

In the Fight Against Advanced Ovarian Cancer.

Partner With Us